Grade ≥ 3 diarrhoea · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
It is very uncertain whether oral changes grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (very low certainty).
1 finding from 1 review
Hand‐foot syndrome (grade ≥ 3) · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral may leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (low certainty).
1 finding from 1 review
Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with curative intent for colorectal cancer with neoadjuvant and/or adjuvant chemotherapy
Oral probably leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (moderate certainty).
1 finding from 1 review
Intervention not reported
Death from all causes · patients with early stage cervical cancer
The intervention probably leads to lower death from all causes (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression · patients with early stage cervical cancer
The intervention probably leads to lower disease progression (moderate certainty).
1 finding from 1 review
Intervention not reported
Grade 4 toxicity3 · patients with early stage cervical cancer
The intervention probably leads to higher grade 4 toxicity3 (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression · patients with early stage cervical cancer
The intervention showed no clear difference in disease progression (low certainty).
1 finding from 1 review
Intervention not reported
Overall 5‐year survival1 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
1008 participants
High
Intervention not reported
Progression‐free 5‐year survival2 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
1170 participants
High
Intervention not reported
Overall 10‐year3 survival · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
925 participants
High
Intervention not reported
Progression‐free 10‐year survival4 · women with stage I/II epithelial ovarian cancer
1 finding from 1 review
no estimate extracted
925 participants
High
Intervention not reported
Adverse events · women with stage I/II epithelial ovarian cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
5‐ year OS · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention probably leads to lower 5‐ year OS (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year PFS · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention probably leads to lower 5‐year PFS (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year OS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention showed no clear difference in 5‐year OS (stage III) (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year PFS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention showed no clear difference in 5‐year PFS (stage III) (moderate certainty).
1 finding from 1 review
Intervention not reported
PFS (stage III/IV) Median · women with advanced (stage III/IV) endometrial cancer after surgery and radiotherapy
The intervention showed no clear difference in PFS (stage III/IV) Median (moderate certainty).
1 finding from 1 review